Ganaxolone

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, Patent, RSE, Biomedical Advanced Research and Development Authority, CV, Therapy, U.S. Department of Defense Strategy for Operating in Cyberspace, SG, Orion Corporation, Human services, United States Patent and Trademark Office, Ganaxolone, Office of Inspector General, U.S. Department of Health and Human Services, Lennox–Gastaut syndrome, API, Forest Law Enforcement and Governance Program, GAAP, Eugnosta tenacia, Medication, Development, Administration, Patient, Investment, Administration for Strategic Preparedness and Response, Marinus, Epilepsy, MAD, Security (finance), Research, FDA, BARDA, Pharmaceutical industry, Medical device, Fine chemical, Cryptocurrency, TSC, RAISE

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2023.
  • Entered exclusive distribution and supply agreement with Biologix for ganaxolone in select markets in the Middle East and North Africa.
  • Recognized $3.3 million in net product revenues for the three months ended March 31, 2023.
  • Net product revenue consists of ZTALMY product sales, which was launched in the U.S. in the third quarter of 2022.

Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 3, 2023
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, Seizure, CV, IV, Therapy, Ganaxolone, CDKL5 deficiency disorder, Brain, CDKL5, Medication, JMP, Patient, GABAA, Epilepsy, Conference, Pharmaceutical industry, Dietary supplement

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present and participate during the following conferences in May.

Key Points: 
  • Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present and participate during the following conferences in May.
  • RBC Annual Healthcare Conference in New York, NY
    May 16 at 10:00 a.m. E.T.
  • Links to the events can be accessed on the Investors and Media page of Marinus’ website at ir.marinuspharma.com/events-and-presentations .
  • Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders.

Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023

Retrieved on: 
Thursday, April 27, 2023
Professional Services, Health, Finance, General Health, Pharmaceutical, Biotechnology, Seizure, CV, IV, Therapy, Ganaxolone, CDKL5 deficiency disorder, Brain, CDKL5, Medication, Patient, GABAA, Epilepsy, Webcast, Pharmaceutical industry

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2023 on May 11, 2023.

Key Points: 
  • Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2023 on May 11, 2023.
  • The Company will host a conference call at 8:30 a.m. Eastern Time on May 11, 2023.
  • Participants may access the conference call via webcast on the Investors and Media page of Marinus’ website at ir.marinuspharma.com/events-and-presentations .
  • Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders.

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Tuesday, March 7, 2023
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, RSE, Office of Inspector General, U.S. Department of Health and Human Services, IV, Security (finance), Development, Therapy, EMA, European Medicines Agency, Ganaxolone, CDKL5 deficiency disorder, Patent, Human services, Growth, SG, Status epilepticus, CDD, Administration, Medicaid, Eugnosta tenacia, Epilepsy, BARDA, GAAP, Patient, Biomedical Advanced Research and Development Authority, ESE, TSC, Medication, CDKL5, Administration for Strategic Preparedness and Response, CV, U.S. Department of Defense Strategy for Operating in Cyberspace, R, Research, Forest Law Enforcement and Governance Program, Pharmaceutical industry, Nursing, Vaccine, Cryptocurrency, RAISE

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2022.
  • “2022 was a year of significant growth and execution for Marinus, underscored by the successful U.S. launch of ZTALMY,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus.
  • Recognized $2.3 million and $2.9 million in net product revenues for the three and twelve months ended December 31, 2022, respectively.
  • Recognized collaboration revenue of $3.0 million in the fourth quarter of 2022 related to the upfront payment associated with the Company’s development and commercialization agreement with Tenacia.

Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2022 Financial Results on March 7, 2023

Retrieved on: 
Monday, February 13, 2023
Biotechnology, Pharmaceutical, Finance, General Health, Health, Professional Services, Clinical Trials, Other Health, Brain, Therapy, Ganaxolone, Seizure, Patient, Webcast, CV, CDKL5 deficiency disorder, IV, GABAA, CDKL5, Epilepsy, Medication, Pharmaceutical industry

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter ended December 31, 2022 on March 7, 2023.

Key Points: 
  • Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter ended December 31, 2022 on March 7, 2023.
  • The Company will host a conference call at 4:30 p.m. Eastern Time on March 7, 2023.
  • Participants may access the conference call via webcast on the Investor page of Marinus’ website at ir.marinuspharma.com/events-and-presentations .
  • Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders.

Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 ZTALMY® Net Product Revenue and Provides Business Update

Retrieved on: 
Thursday, January 5, 2023
Research, Finance, Neurology, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, RAISE, Clinical trial, CDD, CV, CDKL5, Medication, Total, Growth, Patient, Therapy, Hello English (government program), Epilepsy, Ganaxolone, Pharmaceutical industry, Health insurance

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and preliminary U.S. ZTALMY® net product revenue for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and preliminary U.S. ZTALMY® net product revenue for the fourth quarter and year ended December 31, 2022.
  • “We are pleased with the successful launch of ZTALMY resulting from the strong commercial foundation established and look forward to another pivotal year for Marinus and ganaxolone,” said Steven Pfanstiel, Chief Financial Officer of Marinus.
  • “This launch progress validates our focused commercial investment approach for the CDKL5 deficiency disorder indication which we anticipate could become cash flow accretive within two years of launch.
  • Continue to target topline data for the ongoing Phase 3 trials in refractory status epilepticus (RAISE) and tuberous sclerosis complex (TrustTSC) in the second half of 2023 and first quarter of 2024, respectively

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
Friday, December 9, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Security (finance), Therapy, GABAA, Ganaxolone, Financial compensation, Patient, Common stock, Employment, Cyprus Securities and Exchange Commission, Medication, CDKL5, CV, Brain, IV, Epilepsy, Seizure, Pharmaceutical industry

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to two new employees.

Key Points: 
  • (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to two new employees.
  • The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 22,050 shares of its common stock (the Common Stock) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock options were granted as an inducement material to each of the employees entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grant.
  • Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders.

Marinus Pharmaceuticals Announces Presentations and Investor Event at American Epilepsy Society 2022 Annual Meeting

Retrieved on: 
Wednesday, November 30, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, COVID-19, American Epilepsy Society, Maxima and minima, Marinus, 2021 Essex County Council election, AES, EMA, Brain, Patient, Medication, CV, Ganaxolone, Annual general meeting, Webcast, Security (finance), Seizure, Epilepsy, Therapy, IV, GABAA, Clinical trial, CDKL5, FDA, Pharmaceutical industry

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that ganaxolone data from three abstracts, including one late-breaking abstract, will be presented at the upcoming 2022 American Epilepsy Society (AES) Annual Meeting, which will be held December 2-6, 2022, in Nashville, TN.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that ganaxolone data from three abstracts, including one late-breaking abstract, will be presented at the upcoming 2022 American Epilepsy Society (AES) Annual Meeting, which will be held December 2-6, 2022, in Nashville, TN.
  • Marinus will also host a scientific exhibit and investor breakfast event with members of its leadership team to highlight ganaxolones potential across a range of seizure disorders and discuss its commercial progress and strategy.
  • An archived version of the call will be available approximately two hours after the completion of the event on the website.
  • Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders.

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
Friday, November 18, 2022
Health, Pharmaceutical, Common stock, Medication, Brain, Epilepsy, Ganaxolone, CDKL5, Employment, Financial compensation, Cyprus Securities and Exchange Commission, Security (finance), IV, Therapy, CV, Seizure, GABAA, Patient, Pharmaceutical industry

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to 3 new employees.

Key Points: 
  • Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to 3 new employees.
  • These stock option grants have an exercise price of $4.98 per share, which is equal to the closing price of the Common Stock on November 14, 2022 (date of grant for such stock options).
  • The stock options were granted as an inducement material to each of the employees entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grant.
  • Marinus is a commercial stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders.

Marinus Pharmaceuticals Appoints CEO Scott Braunstein, M.D., as Chairman of the Board

Retrieved on: 
Thursday, November 17, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, FDA, Medication, Clinical trial, Summit Medical Group, Brain, Epilepsy, Ganaxolone, J. P. Morgan, CDKL5, Prescription, Albert Einstein College of Medicine, Annual report, Prodrug, Rachel Haurwitz, Security (finance), Marinus, Form 10-K, FTSE Global Equity Index Series, IV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Columbia University Irving Medical Center, Therapy, Trevena Inc, Growth, COVID-19, CV, Seizure, GABAA, Risk, EMA, Food, Patient, Management, Pharmaceutical industry

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that the Board of Directors has appointed Chief Executive Officer (CEO) and Board Director, Scott Braunstein, M.D., as Chairman of the Board.

Key Points: 
  • Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that the Board of Directors has appointed Chief Executive Officer (CEO) and Board Director, Scott Braunstein, M.D., as Chairman of the Board.
  • Newly appointed Lead Independent Board Director for Marinus, Tim M. Mayleben, said, "We are thrilled with the Companys transformation over the last few years under Scotts management.
  • We look forward to complementing the skills and expertise of the Board with new members to support efforts to scale Marinus.
  • I look forward to working with Tim as we evolve and enhance the Marinus Board with additional capabilities, said Chairman and CEO, Scott Braunstein.